AI in Alzheimer disease research has shifted from sparse experimentation to a global deep learning effort
A 25-year bibliometric analysis of artificial intelligence research in Alzheimer disease captures how quickly the field has moved from early computational experiments to large-scale work centered on machine learning, deep learning, and multimodal data. The analysis drew on Web of Science Core Collection records from 1999 through 2023 and identified 5,347 articles, offering a long view of how the research ecosystem has matured around early detection, classification, and biomarker discovery.
The breadth of publication alone tells part of the story. What began as a relatively narrow technical niche has expanded into a major research area with contributions from leading academic centers and high-impact journals. The United States emerged as the most productive country, while the University of London, Harvard University, the University of North Carolina, and the University of California system ranked among the most prolific institutions. In author-level influence, Daoqiang Zhang stood out as the most influential scholar in the field, and NeuroImage carried the greatest influence among journals indexed in the analysis.
A single trend runs through the keyword network: the field now revolves around machine learning and deep learning approaches applied to prediction and diagnosis. That shift is clinically meaningful because Alzheimer disease does not present as a single neat phenotype. It unfolds over years, often before dementia becomes obvious, and the earliest signs are embedded in imaging, cognitive trajectories, and other data streams that human interpretation can miss when viewed in isolation.
This is why the move toward multimodal modeling matters. Alzheimer disease is biologically heterogeneous, and no single signal reliably captures its full course. Imaging, longitudinal clinical data, and other measurable features can be fused by deep learning systems in a way that may better reflect the layered biology of neurodegeneration, synaptic loss, and progressive network dysfunction. The bibliometric pattern suggests that researchers are increasingly trying to build models that do not merely classify disease status, but instead detect patterns early enough to matter for intervention and trial enrichment.
The field is not just getting larger; it is getting more computationally ambitious.
Multimodal modeling is becoming the central technical direction
The keyword co-occurrence analysis points to a clear research pivot: deep learning paired with multimodal data is becoming the preferred route for Alzheimer disease classification and early diagnosis. That trajectory makes biological sense. Alzheimer disease evolves through overlapping pathological processes, and those processes rarely appear in a single modality with equal clarity. Structural and functional imaging, cognitive markers, and potentially other longitudinal features may each capture a different piece of the disease process, while machine learning architectures can integrate those pieces into a more coherent predictive framework.
The analysis also makes clear that the field is still working through two major constraints. First, data diversity remains limited. Research that depends heavily on narrow datasets risks producing models that perform well in one setting and weaken when tested elsewhere. Second, interpretability remains incomplete. In clinical neurology, a model that predicts risk without explaining its decision path can be difficult to trust, especially when the output is supposed to influence diagnosis, prognosis, or patient selection for therapy. The demand is not simply for accuracy. It is for models that can be understood, audited, and carried across health systems with different patient populations and scanner profiles.
Those limitations are familiar in Alzheimer research because the disease itself is deeply variable. Age at onset, comorbidities, vascular burden, education, genetics, and imaging signatures all shape the phenotype. A model trained on one cohort may inadvertently learn local patterns that reflect site-specific data structure more than disease biology. For that reason, the next phase of work needs more than bigger datasets. It needs broader sampling, longitudinal follow-up, and careful external validation across heterogeneous populations.
What the bibliometric map says about the next phase
The publication pattern suggests that Alzheimer AI research is now moving from proof-of-concept classification toward models that can support early diagnosis and biomarker discovery in a more clinically usable way. In practical terms, that means future studies will need to show not only that an algorithm can separate disease from nondisease, but also that it can do so consistently across populations, disease stages, and real-world imaging or clinical workflows.
Longitudinal data may be especially important. Alzheimer disease progresses over time, and static snapshots can flatten that progression into a single label. Models that incorporate repeated measures could better capture trajectory, which is often more informative than one-time assessment for personalized diagnosis and treatment planning. Multimodal integration may also help bridge the gap between mechanism and phenotype by combining anatomical, functional, and clinical signals into a richer profile of neurodegenerative change.
The literature volume identified in this analysis also implies that the research community is now large enough to support more rigorous benchmarking. A mature field should be able to compare methods across standard datasets, evaluate reproducibility, and test whether performance holds outside the development environment. Without that step, even sophisticated deep learning systems risk remaining interesting laboratory tools rather than dependable clinical aids.
One practical challenge sits underneath all of this: Alzheimer disease is common, costly, and diagnostically complex, which makes early prediction attractive, but it also means false confidence can be harmful. A model that appears precise in retrospective work may still fail when asked to face the diversity of everyday neurology clinics. The bibliometric record does not resolve that problem, but it does show where the field is heading and why the pressure is now on generalizability, interpretability, and integration of diverse longitudinal data.
The central message from the 25-year publication pattern is straightforward. AI has become deeply embedded in Alzheimer disease research, with deep learning and multimodal strategies now occupying the field’s center of gravity. The remaining hurdle is not generating more algorithms. It is building models that can be trusted across populations, explained at the bedside, and adapted to the clinical reality of a disease that changes long before it is recognized.